NOT FOR RELEASE, PUBLICATION, OR
DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
Integrated Diagnostics Holdings plc
Update on Treasury Shares Removal
Process
6 September 2024
Integrated Diagnostics Holdings plc
("IDH" or the "Company") refers to the Company's
announcement on 27 August 2024 (the "Buyback Announcement") in relation to
the share buyback under the Egyptian Exchange's special operations
market (OPR) and the Company's repurchase of 18,673,728 EGX Shares
(as defined in the Buyback Announcement) (the "Repurchased Shares") on 26 August 2024
pursuant to that share buyback. As reflected in that announcement,
the Company had previously expected that the removal of the
Repurchased Shares from Misr for Central Clearing, Depository and
Registry (MCDR) to be held in the name of the Company as treasury
shares (the "Removal
Process") would complete on or about 2 September 2024. This
process is underway but will take longer to complete than had
originally been expected and is now expected to complete later in
September 2024. The Company will release a further announcement
once the Removal Process has been completed.
For further information please
contact:
Integrated Diagnostics Holdings
plc
Tarek Yehia
Investor Relations
Director
T: +20 (0)2 3332 1126 | M: +20 10
6882 6678 | tarek.yehia@idhcorp.com
Company Secretary
Company Matters
IDHLondon@linkgroup.co.uk
-Ends-
About Integrated Diagnostics
Holdings (IDH)
IDH is a leading diagnostics
services provider in the Middle East and Africa offering a broad
range of clinical pathology and radiology tests to patients in Egypt,
Jordan, Nigeria, Sudan and Saudi Arabia. The Group's core brands include Al Borg, Al
Borg Scan and Al Mokhtabar in Egypt, as well as Biolab
(Jordan), Echo-Lab (Nigeria), Ultralab and Al Mokhtabar Sudan
(both in Sudan), and Biolab KSA (Saudi Arabia).
With over 40 years of experience, a long track record for quality
and safety has earned the Company a trusted reputation, as well as
internationally recognised accreditations for its portfolio of
over 3 ,000
diagnostics tests. From its base of 601 branches as of 31
December 2023, IDH
served over 8. 5 million
patients and performed more than 36.1 million tests in 2023. IDH will continue to add
laboratories through a Hub, Spoke and Spike business model that
provides a scalable platform for efficient expansion. Beyond
organic growth, the Group targets expansion in appealing markets,
including acquisitions in the Middle Eastern, African, and
East Asian markets where its model is well-suited to capitalise on
similar healthcare and consumer trends and capture a significant
share of fragmented markets. IDH is a Jersey-registered
entity whose Shares are admitted to the equity shares (transition)
category (previously, the standard listing segment) of the Official
List of the UK Financial Conduct Authority and admitted to trading
on the main market for listed securities of the London Stock
Exchange since May 2015 (ticker: IDHC).
Learn more at idhcorp.com.